Venture Partner, Vivo Capital
Dr. Tsay joined Vivo Capital in 2016 as a Venture Partner. Prior to his retirement in 2010 from Thermo Fisher Scientific, Dr. Tsay served as Senior Vice President and Group President of the company’s Specialty Diagnostic business, with worldwide annual revenue of US $2 billions. He was the Group President of Immunodiagnostics of Fisher Scientific prior to Fisher’s merger with Thermo Electron in 2006. From 2000 to 2004 he served as Group President of Clinical Diagnostics of Apogent, which was acquired by Fisher Scientific in 2004. While working for these public companies, he was instrumental in engineering the acquisition of multiple diagnostic companies including Phadia, One Lambda, BRAHMS, Microgenics, Seradyne, Duke Scientifics and Applied Biotech. He was the founder of Diagnostics Reagents Inc., which was acquired by Apogent in 1998. He also cofounded several other diagnostic companies, which were either acquired by a public company or went public. Dr. Tsay currently serves on the board of directors of several emerging medical device companies. He received his B.S. in Chemistry from the National Cheng-Kung University in Taiwan, and his Ph.D. in Organic Chemistry from the University of Rochester, New York.